A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on: December 21,2023 13

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on:December 21,2023 13

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on: October 31,2023 5

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on:October 31,2023 5

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on: December 22,2023 19

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on:December 22,2023 19

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on: October 11,2023 258

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on:October 11,2023 258

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o

Updated on: December 19,2023 10

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o

Updated on:December 19,2023 10

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o

Updated on: October 24,2023 60

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o

Updated on:October 24,2023 60

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023 13

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023 13

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on: December 22,2023 19

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on:December 22,2023 19

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023 27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023 27

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es

Updated on: December 20,2023 21

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es

Updated on:December 20,2023 21

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023 27

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023 27

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on: December 21,2023 10

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on:December 21,2023 10